November 01, 2022
Zimbabwe: Zimbabwe Is the First Country in Africa to Announce Regulatory Approval for Long-Acting Injectable Cabotegravir for HIV Prevention
The Medicines Control Authority of Zimbabwe (MCAZ) announced that it has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV… Read more »
October 17, 2022
Zimbabwe: Zimbabwe Is The First County In Africa To Announce Regulatory Approval For Long-Acting Injectable Cabotegravir For HIV Prevention
Today, the Medicines Control Authority of Zimbabwe announced that it has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV… Read more »